

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sihuan Pharmaceutical Holdings Group Ltd.

四環醫藥控股集團有限公司

(incorporated in Bermuda with limited liability)

(Stock Code: 0460)

VOLUNTARY ANNOUNCEMENT

**POLYCAPROLACTONE MICROSPHERE FACIAL FILLER FOR
INJECTION AND HYALURONIC ACID SODIUM COMPOSITE
SOLUTION FOR INJECTION INDEPENDENTLY DEVELOPED BY
MEIYAN SPACE, A SUBSIDIARY OF SIHUAN PHARMACEUTICAL,
APPROVED FOR MARKET LAUNCH IN HONG KONG**

The board of directors (the “**Board**”) of Sihuan Pharmaceutical Holdings Group Ltd. (the “**Company**” or “**Sihuan Pharmaceutical**”, together with its subsidiaries, the “**Group**”) is pleased to announce that, recently, the Polycaprolactone Microsphere Facial Filler for Injection (the “**PCL**”) and Hyaluronic Acid Sodium Composite Solution for Injection (FL) (the “**skin booster**”), both self-developed and manufactured by the Group’s subsidiary, Meiyang Space Biotechnology (Jilin) Co., Ltd. (“**Meiyang Space**”), have successively been approved for market launch in the Hong Kong Special Administrative Region of China (“**Hong Kong**”). The approved specifications of the Polycaprolactone Microsphere Facial Filler for Injection comprise 0.5 mL/tube, 1.0 mL/tube and 2.0 mL/tube; the approved specifications of the Hyaluronic Acid Sodium Composite Solution for Injection comprise 0.5 mL/tube, 1.0 mL/tube, 1.5 mL/tube, 2.0 mL/tube, 2.5 mL/tube, 3.0 mL/tube and 5 mL/box (containing two 2.5 mL tubes).

Expanding into international markets is one of the Company's key strategies for its medical aesthetics business, and this year marks an acceleration year for its overseas layout. The PCL is a regenerative filler, while the skin booster is a skin quality management product, both representing mainstream categories in the light medical aesthetics sector. Following their launch in mainland China, both products have achieved strong sales and market response. The approvals of these two self-developed products for market launch in Hong Kong not only expand the market space for both products, but also mark a breakthrough in the registration of the Group's medical aesthetic products in Hong Kong. They lay a solid foundation for the Group to deepen its presence in the Hong Kong market and extend its reach across the Asia-Pacific region, supporting its long-term goal of becoming an international medical aesthetics company. Meanwhile, these approvals demonstrate that the Group's research and development, manufacturing and quality management systems for medical aesthetic products meet the regulatory requirements in Hong Kong. They also provide valuable practical experience for the registration and certification of multiple additional self-developed medical aesthetic products across multiple jurisdictions worldwide, further strengthening the foundation for the global development of the Group's medical aesthetics segment.

ABOUT POLYCAPROLACTONE MICROSPHERE FACIAL FILLER FOR INJECTION

Polycaprolactone Microsphere Facial Filler for Injection contains a polycaprolactone gel carrier that can provide immediate filling and improve facial depressions. As the gel carrier is degraded and absorbed, the polycaprolactone microspheres can induce tissue regeneration and achieve a long-lasting filling effect. In April 2025, the PCL was approved for market launch by the National Medical Products Administration of China for the correction of moderate-to-severe nasolabial fold wrinkles.

ABOUT HYALURONIC ACID SODIUM COMPOSITE SOLUTION FOR INJECTION

Hyaluronic Acid Sodium Composite Solution for Injection, as China's first composite solution skin booster containing L-carnosine approved for direct facial use, has multiple effects such as hydrating and moisturizing, antioxidant, anti-glycation and anti-inflammatory effects. To date, the skin booster has been approved for market launch by the National Medical Products Administration of China, comprising twelve specifications ranging from 0.5 mL/tube to 5 mL/tube. It is used for injection into the superficial dermis of the face to temporarily improve skin dryness and dullness in adults.

ABOUT MEIYAN SPACE

Meiyan Space is a new type of “one-stop” medical aesthetic platform incubated by Sihuan Pharmaceutical, through the globalization layout, comprehensive and professional medical aesthetic product matrix, product research and development, registration, production and sales of an integrated structure, is dedicated to building a leading company featuring a full medical aesthetics product matrix in China by leveraging the rigour and innovation of pharmaceutical companies. Meiyan Space continues to build a complete product matrix covering the whole life cycle needs of beauty lovers through the dual-engine drive of “self-research + BD”, with more than 60 products in the pipeline, covering the basic categories of light medical aesthetic, including fillers, contouring, support, optoelectronic equipment and skin management. Meanwhile, Meiyan Space has strong independent research and development and technology transfer strength, the professional BD team and R&D team in China and abroad can quickly promote the research and development and launching of medical aesthetic products. At present, Meiyan Space has established three production bases globally, with a perfect quality management system and effective risk management for the whole life cycle of products. Its experienced medical aesthetic sales team, nationwide sales network and well developed system can quickly promote the sales of products. Most of the sales team members of Meiyan Space come from multinational medical aesthetic and pharmaceutical enterprises, with rich experience in the sales of medical aesthetic products, and work closely with dozens of agents, the sales network has covered more than 370 cities and more than 9,000 medical aesthetic institutions.

ABOUT SIHUAN PHARMACEUTICAL

Founded in 2001 and listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2010, Sihuan Pharmaceutical is an international medical aesthetics and pharmaceutical company led by innovation, with an independent and leading research and development technology platform, a rich global product pipeline, strong product registration capability, a full dosage form production platform with high efficiency and low cost and a mature and excellent sales system. Adhering to the overall strategic goal for the “full promotion of a two-wheel drive strategy of its medical aesthetics and biopharmaceutical businesses”, Sihuan Pharmaceutical endeavors to build itself into a leading medical aesthetics and biopharmaceutical company in China.

This announcement is being made by the Company on a voluntary basis to update the investing public on the Group's latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, medical equipment, treatment or orally consumed product.

By order of the Board
Sihuan Pharmaceutical Holdings Group Ltd.
Dr. Che Fengsheng
Chairman and Executive Director

Hong Kong, 20 October 2026

As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong and Ms. Chen Yanling; the non-executive director of the Company is Mr. Che Yuxuan; and the independent non-executive directors of the Company are Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.